A double-blind, randomized, placebo-controlled clinical trial with a parallel-group design involving 26 MS patients treated with interferon beta (13 of them receiving a supplement of melatonin and the other 13 receiving placebo) with 1-year of follow-up showed a lack of beneficial effect of melatonin on the number of relapses, EDSS, appearance of new lesions in magnetic resonance imaging (MRI), fatigue and depression, although patients under melatonin showed a trend towards improvement in the performance of Multiple Sclerosis Functional Scale [ 54 ].
1
—
—